Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Documenti analoghi

• Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction
  di: Esraa Eloseily, et al.
  Pubblicazione: (2024)
• Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
  di: Ekemini A. Ogbu, et al.
  Pubblicazione: (2024)
• Do We Need Distinct Pediatric Classification Criteria for Rheumatic Diseases That Affect Both Children and Adults?
  di: Coziana Ciurtin, et al.
  Pubblicazione: (2025)
• ArtEM: Enhancing the Understanding of Integer and Modular Arithmetic Through Interactive Learning Software
  di: Violeta Migallón, et al.
  Pubblicazione: (2025)
• Letting go of founder's syndrome: Why nonprofit leaders must evolve with purpose
  di: Brittan Stockert
  Pubblicazione: (2025)